Monica Mita, MD
Medical Oncology · San Antonio, TXNPI 1760450043
Payments from drug & device makers
Across 381 payments — averaging $13,562 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3.5M
- Pfizer$532K
- Seagen Inc.$229K
- Tesaro, Inc.$186K
- Incyte Corporation$134K
- Otsuka Pharmaceutical Co., Ltd.$119K
- plus $492K from 32 others
Across 10 payments — averaging $1181.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
- AbbVie$4K
- Pfizer$3K
- Bristol Myers Squibb$886
What the payments were for
- Consulting fees$24,42384%
- Speaking & faculty fees$2,5059%
- Travel & lodging$7663%
- Food & beverage$1,5365%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 41 | $3,475,512 |
| Pfizer | 63 | $532,158 |
| Seagen Inc. | 35 | $228,540 |
| Tesaro, Inc. | 17 | $186,414 |
| Incyte Corporation | 105 | $133,704 |
| Otsuka Pharmaceutical Co., Ltd. | 15 | $119,339 |
| EMD Serono, Inc. | 3 | $58,056 |
| AbbVie | 12 | $57,094 |
| GSK | 5 | $55,828 |
| Beone Medicines USA, Inc. | 2 | $48,592 |
| Boston Scientific | 3 | $46,268 |
| Boehringer Ingelheim International GmbH | 9 | $45,385 |
| Hoffmann-la Roche Limited | 9 | $40,236 |
| Theratechnologies Inc. | 2 | $30,330 |
| Daiichi Sankyo Inc. | 3 | $21,739 |
| Beigene AUS Pty Ltd | 3 | $15,837 |
| Sanofi US Services Inc. | 7 | $13,504 |
| AstraZeneca | 5 | $11,865 |
| Genentech, Inc. | 6 | $9,955 |
| Eli Lilly | 4 | $8,308 |
| Beigene USA, Inc. | 5 | $7,835 |
| Roche Products Limited | 2 | $5,765 |
| Gilead | 4 | $3,654 |
| Sanofi | 1 | $3,270 |
| Athenex Pharmaceutical Division, LLC | 5 | $2,175 |
| Eisai Inc. | 1 | $1,875 |
| Bayer | 1 | $1,199 |
| Tersera Therapeutics LLC | 3 | $1,182 |
| Beigene, Ltd. | 1 | $556 |
| Taiho Oncology, Inc. | 1 | $438 |
| Boehringer Ingelheim | 1 | $394 |
| E.r. Squibb & Sons, L.L.C. | 1 | $63 |
| Novartis | 1 | $60 |
| Tempus AI, Inc | 1 | $45 |
| GE HealthCare | 1 | $41 |
| Puma Biotechnology, Inc. | 1 | $36 |
| Genentech USA, Inc. | 1 | $27 |
| Amgen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SARCLISA$3,979
- DATROWAY$2,460
- LENVIMA$1,875
- Oral Paclitaxel$1,500
- Encequidar$1,500
- Vitrakvi$1,199
- ZOLADEX$1,157
- Trodelvy$242
- Enhertu$150
- IBRANCE$119
How this compares
$5,167,297 in reported general payments places this provider in the 85th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 185 | $3,798 |
| Exemestane | 11 | $809 |
| Ibandronate Sodium | 17 | $572 |
| Letrozole | 28 | $410 |
| Gabapentin | 30 | $204 |
| Potassium Chloride | 16 | $187 |
| Prochlorperazine Maleate | 11 | $121 |
| Dexamethasone | 15 | $52 |
| Ondansetron Hcl | 12 | $51 |
| Lorazepam | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Antonio
- Amita PatnaikSan Antonio$17.8M
- Anthony TolcherSan Antonio$15.9M
- Sukeshi AroraSan Antonio$9.1M
- John SarantopoulosSan Antonio$9M
- Virginia KaklamaniSan Antonio$5.5M
- Lei ZhengSan Antonio$5.3M
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.